fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Rifabutin

All products: Limited Use (codes 103, 104)

Mycobutin · DIN 02063786 · 150 mg · capsule

Limited Use, Reason for Use code 103, 104 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 103, 104 required
Write on scriptone applicable Reason for Use code, 103 or 104 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 103, 104
Coverage limit: For the prevention of Mycobacterium Avium Intracellular (MAI) in: Reason for Use code 103 Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis; Coverage limit: LU Authorization Period: 1 year Reason for Use code 104 Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Mycobutin · DIN 02063786 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2005-02-16 · brand MYCOBUTIN · ATC J04AB04 RIFABUTIN · form Capsule · route Oral · ingredients RIFABUTIN 150 MG · company Atlantic nanofend group ltd. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mycobutin: Formulary list price $6.33 per unit (the source does not state the unit; exact figure $6.3342). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02063786)

Source record
DIN 02063786: Mycobutin Raw flags: sec12=Y, sec3=Y Item: 081600018; group id 56; item number 0114; lccId 00005; manufacturer id PFI Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.3342; ministry $6.3342 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02063786 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18081
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (J04A, J04AB): coverage varies; not interchangeable

  • Rifampin (Rofact): general benefit
  • Ethambutol (Myambutol): general benefit, not a benefit
Other drugs in the same formulary class (08:16 Antitubercular Agents) and how they are covered

Matched class: 08:16 Antitubercular Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: RIFAMPIN Some products covered without a code (check the product listing): ETHAMBUTOL HCL 08:16 Antitubercular Agents

RIFAMPIN

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

ETHAMBUTOL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 400mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:16
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: disseminated mycobacterium avium complex
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AZITHROMYCIN · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) Prevention of Disseminated Mycobacterium Avium Complex (MAC) Disease Azithromycinalone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections (MAC) disease in persons with advanced HIV infections (see 14 Clinical Trials). PM: https://pdf.hres.ca/dpd_pm/00085669.PDF; date AUG 7, 2026; DIN 02261634; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. INDICATIONS MYCOBUTIN (rifabutin) is indicated for: • the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection (CD4+ cell count 200/mm3 with an AIDS defining diagnosis, or CD4+ cell count  100/mm3 without an AIDS defining diagnosis). To reduce the development of drug-resistant bacteria and maintain the effectiveness of MYCOBUTIN and other antibacterial drugs, MYCOBUTIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of MYCOBUTIN in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (≥65 years of age): No data are available to Health C… https://pdf.hres.ca/dpd_pm/00073866.PDF PM date: SEPT 24, 2003 Source product: MYCOBUTIN; DIN 02063786; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18